The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
